Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284340 | 0.86 | MCHR1 (0.58) | MCHR1KCNH2HRH3 | |
| SCHEMBL2571449 | 0.85 | MCHR1 (0.66) | MCHR1KCNH2HRH3 | |
| SCHEMBL14150356 | 0.83 | MCHR1 (0.56) | MCHR1KCNH2HRH3 | |
| SCHEMBL1724743 | 0.82 | MCHR1 (0.56) | MCHR1KCNH2HRH3 | |
| SCHEMBL1004916 | 0.82 | MCHR1 (0.65) | MCHR1KCNH2HRH3 | |
| SCHEMBL12285578 | 0.81 | MCHR1 (0.55) | MCHR1KCNH2HRH3 | |
| SCHEMBL2554993 | 0.80 | MCHR1 (0.54) | MCHR1KCNH2HRH3 | |
| SCHEMBL1005304 | 0.80 | MCHR1 (0.60) | MCHR1KCNH2HRH3 | |
| SCHEMBL1000664 | 0.80 | MCHR1 (0.62) | MCHR1KCNH2HRH3 | |
| SCHEMBL1753659 | 0.79 | MCHR1 (0.65) | MCHR1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558094-A1 | PYRIDONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2011127643-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130086-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130086-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011127643-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MC1R, MC5R, MCHR1 | MCHR1 3/4885KCNH2 3313/4885HRH3 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.